Shanghai-based Alebund Pharmaceuticals has announced the completion of a Series C financing round, raising RMB 550 million (USD 75.04 million). The round was led by Yangzhou Guojin Investment Group Co. Ltd and Kingray Capital, both renowned healthcare funds. The proceeds will be used to enhance the development and commercialization of Alebund’s kidney disease pipelines and to advance multiple clinical programs.
Specific Projects and Market Expansion
The funding will specifically support the market filing in China for AP301, a best-in-class iron-based phosphate binder, and its global pivotal study. Additionally, it will fund the US/China Phase II study for AP306, a first-in-class pan phosphate transporter inhibitor. The funds will also be used to further expand the commercial reach of Mircera in China.
About Mircera and Alebund’s Partnership with Roche
Mircera (methoxy polyethylene glycol-epoetin beta) is a long-acting erythropoietin (ESA) developed by Swiss giant Roche. It is used to treat anemia related to chronic kidney disease (CKD) and is the first of its kind globally, allowing monthly administration. Mircera was approved in China in April 2018 for the treatment of CKD anemia in patients undergoing treatment with erythropoietic stimulants. In October 2023, Alebund struck a commercialization deal with Roche for exclusive promotion rights to the drug in mainland China.-Fineline Info & Tech
